Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2008 1
2016 1
2017 2
2018 2
2019 5
2020 3
2021 2
2022 2
2023 5
2024 11
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease.
Rosa-Baez C, Rangel-Pelaez C, Rodriguez-Martin I, Kerick M, Guillen-Del-Castillo A, Simeon-Aznar CP, Callejas JL, Voskuyl AE, Kreuter A, Distler O, Proudman SM, Nikpour M, Hunzelmann N, De Vries-Bouwstra JK, Herrick AL, Allanore Y, Beretta L, Mayes MD, Denton CP, Assassi S, Martin J, Acosta-Herrera M; International SSc Group; Australian Scleroderma Interest Group (ASIG). Rosa-Baez C, et al. RMD Open. 2025 Aug 12;11(3):e005754. doi: 10.1136/rmdopen-2025-005754. RMD Open. 2025. PMID: 40803819 Free PMC article.
Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.
Ross L, Hansen D, Proudman S, Khanna D, Herrick AL, Stevens W, Baron M, Nikpour M; Australian Scleroderma Interest Group (ASIG), Canadian Scleroderma Research Group (CSRG), the Scleroderma Clinical Trials Consortium Activity Index Working Group. Ross L, et al. Arthritis Rheumatol. 2024 Nov;76(11):1635-1644. doi: 10.1002/art.42939. Epub 2024 Aug 26. Arthritis Rheumatol. 2024. PMID: 38937146
Measures of disease status in systemic sclerosis: A systematic review.
Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Nikpour M; Damage Index Working Group of the Scleroderma Clinical Trials Consortium. Tay T, et al. Among authors: ferdowsi n. Semin Arthritis Rheum. 2017 Feb;46(4):473-487. doi: 10.1016/j.semarthrit.2016.07.010. Epub 2016 Jul 29. Semin Arthritis Rheum. 2017. PMID: 27765344
N-terminal pro-brain natriuretic peptide is associated with pulmonary hypertension or diastolic dysfunction in patients with systemic sclerosis: An Australian prospective cross-sectional study.
Ha FJ, Brown Z, Stevens W, Prior D, Ross L, Ferdowsi N, Nikpour M, Burns AT. Ha FJ, et al. Among authors: ferdowsi n. J Scleroderma Relat Disord. 2024 Oct;9(3):178-184. doi: 10.1177/23971983241249209. Epub 2024 May 9. J Scleroderma Relat Disord. 2024. PMID: 39381051 Free PMC article.
Multidisciplinary team discussion: the emerging gold standard for management of cardiopulmonary complications of connective tissue disease.
Fairley JL, Ross L, Burns A, Prior D, Conron M, Rouse H, McDonald J, MacIsaac A, La Gerche A, Morrisroe K, Ferdowsi N, Quinlivan A, Brown Z, Stevens W, Nikpour M. Fairley JL, et al. Among authors: ferdowsi n. Intern Med J. 2023 Oct;53(10):1919-1924. doi: 10.1111/imj.16233. Epub 2023 Sep 29. Intern Med J. 2023. PMID: 37772776 Free PMC article. Review.
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
Barbacki A, Baron M, Wang M, Zhang Y, Stevens W, Sahhar J, Proudman S, Nikpour M, Man A; Australian Scleroderma Interest Group and the Canadian Scleroderma Research Group. Barbacki A, et al. Arthritis Care Res (Hoboken). 2023 Mar;75(3):640-647. doi: 10.1002/acr.24873. Epub 2022 Nov 15. Arthritis Care Res (Hoboken). 2023. PMID: 35226416
35 results